

I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to the Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450

on August 23, 2006

Glenn P. Ladwig
Glenn P. Ladwig, Patent Attorney


INFORMATION DISCLOSURE
STATEMENT

Examining Group 1646

Patent Application

Docket No. USF-T193XC1

Serial No. 10/544,146



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : (Not yet assigned)
Art Unit : 1646
Applicants : Shyam S. Mohapatra, Weidong Zhang
Serial No. : 10/544,146 ✓
Filed : August 2, 2005
For : Vectors for Regulating Gene Expression

MS AMENDMENT
Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT
UNDER 37 C.F.R. §§1.97 AND 1.98

Sir:

In accordance with 37 C.F.R. §1.56, the references listed on the attached form PTO/SB/08 are being brought to the attention of the examiner for consideration in connection with the examination of the above-identified patent application. A copy of each cited reference is enclosed. However, the applicants have not submitted copies of the published U.S. applications cited on attached Form PTO/SB/08 pursuant to 37 C.F.R. §1.98(a)(2)(ii).

The applicants respectfully assert that the substantive provisions of 37 C.F.R. §§1.97 and 1.98 are met by the foregoing statement.

Respectfully submitted,

Glenn P. Ladwig
Glenn P. Ladwig

Patent Attorney

Registration No. 46,853

Phone No.: 352-375-8100

Fax No.: 352-372-5800

Address: P.O. Box 142950

Gainesville, FL 32614-2950

GPL/mv

Attachments: Form PTO/SB/08 (5 pages); copies of some references cited therein

J:\USFT193XC1\PTO\IDS.pto.doc\DNB/mv

6



PTO/SB/08A (08-03)

Approved for use through 07/31/2006. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/544,146
				Filing Date	August 2, 2005
				First Named Inventor	Shyam S. Mohapatra
				Art Unit	1646
				Examiner Name	
Sheet	1	of	5	Attorney Docket Number	USF-T193XC1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U1	US-2005/0266093 A1	12-01-2005	Mohapatra	All
	U2	US-2005/0159385 A1	07-21-2005	Mohapatra	All
	U3	US-2005/0158327 A1	07-21-2005	Mohapatra et al.	All
	U4	US-2004/0175384 A1	09-09-2004	Mohapatra et al.	All
	U5	US-2004/0029275 A1	02-12-2004	Brown et al.	All
	U6	US-2004/0023390 A1	02-05-2004	Davidson et al.	All
	U7	US-2004/0019001 A1	01-29-2004	McSwiggen	All
	U8	US-2004/0018176 A1	01-29-2004	Tolentino et al.	All
	U9	US-2004/0009152 A1	01-15-2004	Mohapatra et al.	All
	U10	US-2004/0002077 A1	01-01-2004	Taira et al.	All
	U11	US-2003/0198624 A1	10-23-2003	Mohapatra et al.	All
	U12	US-2003/0190635 A1	10-09-2003	McSwiggen	All

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)				
	F1	WO 2005/056021 A1	06-23-2005	Univ. of South Florida	All	
	F2					
	F3					
	F4					

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT <i>(use as many sheets as necessary)</i>				Complete if Known	
				Application Number	10/544,146
				Filing Date	August 2, 2005
				First Named Inventor	Shyam S. Mohapatra
				Art Unit	1646
				Examiner Name	
Sheet	2	of	5	Attorney Docket Number	USF-T193XC1

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number - Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	U13	US-2003/0175950 A1	09-18-2003	McSwiggen	All
	U14	US-2003/0175772 A1	09-18-2003	Wang	All
	U15	US-2003/0170891 A1	09-11-2003	McSwiggen	All
	U16	US-2003/0166282 A1	09-04-2003	Brown et al.	All
	U17	US-2003/0157691 A1	08-21-2003	Qin et al.	All
	U18	US-2003/0148519 A1	08-07-2003	Engelke et al.	All
	U19	US-2003/0143732 A1	07-31-2003	Fosnaugh et al.	All
	U20	US-2003/0139363 A1	07-24-2003	Kay et al.	All
	U21	US-2003/0068333 A1	04-10-2003	Mohapatra et al.	All
	U22	US-2002/0173478 A1	11-21-2002	Gewirtz	All
	U23	US-10/544,145	08-02-2005	Mohapatra et al. (patent application)	All
	U24	US-10/581,580	06-02-2006	Mohapatra et al. (patent application)	All
	U25	US-10/655,873	09-05-2003	Mohapatra et al. (patent application)	All

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
		Country Code ³ - Number ⁴ - Kind Code ⁵ (if known)					
	F1						
	F2						

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. ¹ Applicant's unique citation designation number (optional). ² See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard T.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/544,146	
			Filing Date	August 2, 2005	
			First Named Inventor	Shyam S. Mohapatra	
			Group Art Unit	1646	
			Examiner Name		
Sheet	3	of	5	Attorney Docket Number	USF-T193XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R1	ADELMAN, Z.N. <i>et al.</i> "RNA silencing of dengue virus type 2 replication in transformed C6/36 mosquito cells transcribing an inverted-repeat RNA derived from the virus genome" <i>J. Virology</i> , 2002, 76:12925-12933.	
	R2	ADELMAN, Z.N. <i>et al.</i> "Sindbis virus-induced silencing of dengue viruses in mosquitoes" <i>Insect Mol Biol.</i> , 2001, 10:265-273.	
	R3	ABBAS-TERKI, T. <i>et al.</i> "Lentiviral-mediated RNA interference" <i>Human Gene Therapy</i> , 2002, 13:2197-2201.	
	R4	BANCHEREAU, J. and STEINMAN, R.M. "Dendritic cells and the control of immunity" <i>Nature</i> , 1998, 392:245-252.	
	R5	BLAIR, C.D. <i>et al.</i> "Molecular strategies for interrupting arthropod-borne virus transmission by mosquitoes" <i>Clin Microbiol Rev</i> , 2000, 13:651-661.	
	R6	BUELER, H. "Adeno-associated viral vectors for gene transfer and gene therapy" <i>Biol Chem</i> , 1999, 380:613-622.	
	R7	CAPLEN, N. <i>et al.</i> "Specific inhibition of gene expression by small double-stranded RNAs in invertebrate and vertebrate systems" <i>Proc. Natl. Acad. Sci. USA</i> , 2001, 98:9742-9747.	
	R8	CAPLEN, N.J. <i>et al.</i> "Inhibition of viral gene expression and replication in mosquito cells by dsRNA-triggered RNA interference" <i>Mol Ther</i> , 2002, 6:243-251.	
	R9	ELBASHIR, S.M. <i>et al.</i> "Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells" <i>Nature</i> , 2001, 411:494-498.	
	R10	FIRE, A. "RNA-triggered gene silencing" <i>Trends Genet</i> , 1999, 15:358-363.	
	R11	HAMMOND, S.M. <i>et al.</i> "Argonaute2, a link between genetic and biochemical analyses of RNAi" <i>Science</i> , 2001, 293:1146-1150.	
	R12	HO, L.J. <i>et al.</i> "Infection of human dendritic cells by dengue virus causes cell maturation and cytokine production" <i>J Immunol</i> , 2001, 166:1499-1506.	
	R13	HUTVÄGNER, G. <i>et al.</i> "A cellular function for the RNA-interference enzyme dicer in the maturation of the <i>let-7</i> small temporal RNA" <i>Science</i> , 2001, 293:834-838.	

Examiner Signature	Date Considered
--------------------	-----------------

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/544,146	
			Filing Date	August 2, 2005	
			First Named Inventor	Shyam S. Mohapatra	
			Group Art Unit	1646	
			Examiner Name		
Sheet	4	of	5	Attorney Docket Number	USF-T193XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R14	ILVES, H. <i>et al.</i> "Retroviral vectors designed for targeted expression of RNA polymerase III-driven transcripts: a comparative study" <i>Gene</i> , 1996, 171:203-208.	
	R15	KAY, M.A. <i>et al.</i> "Viral vectors for gene therapy: the art of turning infectious agents into vehicles of therapeutics" <i>Nature Med</i> , 2001, 7:33-40.	
	R16	LIBRATY, D.H. <i>et al.</i> "Human dendritic cells are activated by dengue virus infection: enhancement by gamma interferon and implications for disease pathogenesis" <i>J Virol</i> , 2001, 75:3501-3508.	
	R17	LUDEWIG, B. <i>et al.</i> "Protective antiviral cytotoxic T cell memory is most efficiently maintained by restimulation via dendritic cells" <i>J Immunol</i> , 1999, 163:1839-1844.	
	R18	MAROVICH, M. <i>et al.</i> "Human dendritic cells as targets of dengue virus infection" <i>J Invest Dermatol Symp Proc.</i> , 2001, 6:219-224.	
	R19	MEN, R. <i>et al.</i> "Dengue type 4 virus mutants containing deletions in the 3' noncoding region of the RNA genome: analysis of growth restriction in cell culture and altered viremia pattern and immunogenicity in Rhesus monkeys" <i>J Virol</i> , 1996, 70:3930-3937.	
	R20	PAUL, C.P. <i>et al.</i> "Effective expression of small interfering RNA in human cells" <i>Nature Biotech.</i> , 2002, 20:505-508.	
	R21	PONNAZHAGAN, S. <i>et al.</i> "Adeno-associated virus type 2-mediated transduction of human monocyte-derived dendritic cells: implications for ex vivo immunotherapy" <i>J Virol</i> , 2001, 75:9493-9501.	
	R22	PROUTSKI, V. <i>et al.</i> "Secondary structure of the 3' untranslated region of flaviviruses: similarities and differences" <i>Nucleic Acids Res</i> , 1997, 25:1194-1202.	
	R23	PROVOST, P. <i>et al.</i> "Ribonuclease activity and RNA binding of recombinant human Dicer" <i>Embo J</i> , 2002, 21:5864.	
	R24	RAUSCHER, S. <i>et al.</i> "Secondary structure of the 3'-noncoding region of flavivirus genomes: comparative analysis of base pairing probabilities" <i>RNA</i> , 1997, 3:779-791.	
	R25	ROY, K. <i>et al.</i> "Oral gene delivery with chitosan-DNA nanoparticles generates immunologic protection in a murine model of peanut allergy" <i>Nat Med</i> , 1999, 5:387-391.	
	R26	SRIVASTAVA, A. "Obstacles to human hematopoietic stem cell transduction by recombinant adeno-associated virus 2 vectors" <i>J Cell Biochem Suppl</i> , 2002, 38:39-45.	

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/544,146	
			Filing Date	August 2, 2005	
			First Named Inventor	Shyam S. Mohapatra	
			Group Art Unit	1646	
			Examiner Name		
Sheet	5	of	5	Attorney Docket Number	USF-T193XC1

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	R27	STÄMPFLI, M.R. <i>et al.</i> "GM-CSF transgene expression in the airway allows aerosolized ovalbumin to induce allergic sensitization in mice" <i>J Clin Invest</i> , 1998, 102:1704-1714.	
	R28	STARK, G.R. <i>et al.</i> "How cells respond to interferons" <i>Annu Rev Biochem</i> , 1998, 67:227-264.	
	R29	TUSCHL, T. "Expanding small RNA interference" <i>Nature Biotechnol.</i> , 2002, 20:446-448.	
	R30	VAUGHN, D.W. <i>et al.</i> "Dengue in the early febrile phase: viremia and antibody responses" <i>J Infect Dis</i> , 1997, 176:322-330.	
	R31	WALTER, D.M. <i>et al.</i> "IL-18 gene transfer by adenovirus prevents the development of and reverses established allergen-induced airway hyperreactivity" <i>J Immunol</i> , 2001, 166:6392-6398.	
	R32	WU, S.J. <i>et al.</i> "Human skin Langerhans cells are targets of dengue virus infection" <i>Nature Med</i> , 2000, 6:816-820.	
	R33	ZAISS, A-K. <i>et al.</i> "Differential activation of innate immune responses by adenovirus and adeno-associated virus vectors" <i>J Virol</i> , 2002, 76:4580-4590.	
	R		
	R		
	R		
	R		
	R		
	R		

Examiner Signature		Date Considered	
--------------------	--	-----------------	--

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, P.O. Box 1450, Alexandria, VA 22313-1450. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

If you need assistance in completing the form, call 1-800-PTO-9199 (1-800-786-9199) and select option 2.